Navigation Links
Vermillion Reports Third Quarter 2013 Results
Date:11/14/2013

AUSTIN, Texas, Nov. 14, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the third quarter ended September 30, 2013.

Q3 2013 Financial Results
Total revenue in the third quarter of 2013 was $330,000 compared to $319,000 in the same year-ago quarter. Third quarter 2013 revenue was comprised of $216,000 in OVA1® product sales and $114,000 in license revenue.

Third quarter of 2013 product revenue was derived from 4,328 OVA1 tests performed at the fixed $50 per test as reported by Quest Diagnostics. This represents a 5.6% increase in test volume compared to approximately 4,100 OVA1 tests performed in the year-ago quarter. Although covered lives have decreased to approximately 67.0 million due to the previously announced BlueCross BlueShield Technical Evaluation Center position, it did not affect test sale volumes for the quarter.

The OVA1 product revenue in both periods does not include the additional royalty component of revenue based on 33% of Quest Diagnostics gross margin. Vermillion recognizes this portion of revenue when it is reported by Quest Diagnostics in an annual 'true-up' after the end of the calendar year. The true-up is based on reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final.

Total operating expenses were $2.6 million in both the third quarter of 2013 and the same year-ago quarter. For the nine months ended September 30, 2013, total operating expenses were $7.9 million as compared to $9.0 million in the same year-ago period.

Net loss for the third quarter was $2.3 million or $(0.10) per share, as compared to a net loss of $2.0 million or $(0.13) per share in the same year-ago quarter. For the nine months ended September 30, 2013, net loss was $7.0 million or $(0.36) per share as compared to a net loss of $5.8 million or $(0.39
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
3. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
4. Vermillion Appoints Dr. Eric Varma to its Board of Directors
5. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
6. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
7. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
8. Vermillion Reports Fourth Quarter and Full Year 2012 Results
9. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
10. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
11. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... VANCOUVER, British Columbia , May 30, 2015 /PRNewswire/ ... today that results from a retrospective analysis of the ... therapy in men with metastatic castrate-resistant prostate cancer (CRPC) ... effect of clusterin inhibition in men at risk for ... in the trial had at least two of five ...
(Date:5/30/2015)... CAMBRIDGE, Massachusetts y SPARTANBURG ... 30, 2015 - Nueva ... clínico terapéutico para pacientes con cáncer en los ... Research Network y Molecular Health proporcionarán a los ...   La Guardian Research Network y ...
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
Breaking Medicine Technology:OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6
... 2011 ConvaTec Healthcare, a world-leading developer, manufacturer and ... care, today announced that, following a review of current ... refinancing of its senior secured term loans originally entered ... ConvaTecConvaTec is a leading developer and marketer of innovative ...
... March 17, 2011 Giant Eagle®, the region,s leading ... Association,s (ADA) prestigious Chairman,s Citation Award. Giant ... which recognizes the outstanding accomplishments of individuals, corporations, institutions ... and have had a positive impact in advancing the ...
Cached Medicine Technology:ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 2ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 3Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 2Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 3
(Date:5/30/2015)... York, New York (PRWEB) May 30, 2015 ... to pay $100 million in punitive and compensatory ... ) plaintiff who suffered serious complications following implantation ... According to a verdict rendered on May 28th ... $25 million in compensatory damages after the jury ...
(Date:5/30/2015)... Belton, Texas (PRWEB) May 30, 2015 ... Client Services Web Portal that gives hospices the ability ... the industry. Because of this business model, EHO has ... offer better pricing to its clients and survive among ... interface with hospice management systems three years ago, it ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Nicole ... the Disability Income Associate (DIA) designation to further ... DIA designation is designed for insurance advisors, health ... further their knowledge and expertise associated with the ... the DIA designation is only the latest accomplishment ...
(Date:5/30/2015)... 30, 2015 The Brain Fitness Education ... with ONEgeneration Senior Enrichment Center, headed by 1Heart Client ... Guzman and Brain Fitness Program Director Tee Barr. , ... learned that there are many ways to enrich and ... the residents the different ways to overcome dementia and ...
(Date:5/30/2015)... Wixom, Michigan: Proof. Pest Control, a family-owned company ... new twist to its robust line of services-a 100% ... for general pest management. , “We like killing ... Branch Manager. “The average person cringes when they see a ... problems that most people don’t even want to think about. ...
Breaking Medicine News(10 mins):Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:Proof. Pest Control-Now Offering 100% Organic Pest Control in Southeast Michigan 2
... Dr. Khanna has found PRELEX is better than Lasik for individuals over ... longer lasting, prevents the development of cataracts, and does not induce dry ... ... Dr. Khanna has found PRELEX is better than Lasik for individuals ...
... The Generic Pharmaceutical Association (GPhA) released the following statement ... the nomination of Dr. Margaret Hamburg as Commissioner and ... Food and Drug Administration (FDA)."GPhA stands ready to work ... the Agency as it carries out its mission to ...
... reduce itching, improve quality of life, study finds , , ... Chinese medicine, including tea and acupuncture, may safely and ... finds. , Use of Erka Shizheng Herbal ... months greatly reduced the severity of the itchy, red ...
... with Updated Interoperability Requirements , ... ... -- The Certification Commission for Healthcare Information Technology (CCHIT®) ... 4.0.1 is a CCHIT Certified® 08 Ambulatory EHR meets ...
... Kurzweil , described by Forbes magazine as "the ultimate ... (D-IA), health and wellness expert Dr. Deepak Chopra , ... and Chief Scientific Officer Dr. Mehmood Khan and three ... Race and Reconciliation in America: Health and Wellness for ...
... As a result of the FDA expanding the Peanut Corporation of ... lla related recall to include all peanut ingredient ... Weaver Popcorn Company, Inc. has issued a precautionary voluntary recall for ... , s End (R) Chocolatey Peanut ...
Cached Medicine News:Health News:PRELEX is the Answer for Baby Boomers Vision Needs 2Health News:GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA 2Health News:Advanced Data System's MedicsDocAssistant™ EHR Receives 08 CCHIT Certification 2Health News:Advanced Data System's MedicsDocAssistant™ EHR Receives 08 CCHIT Certification 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 2Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 4Health News:Weaver Popcorn Company Issues a Nationwide Precautionary Voluntary Recall of 12 oz. (340g) Trail's End(R) Chocolatey Peanut Clusters 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: